BIO-Europe® 2016: Dimerix CEO explains company's different drug combo R&D strategy

November 25, 2016
Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company's unusual business model. They discuss Dimerix's Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix's pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix's lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.
Previous Video
BIO-Europe® 2016: How are regulatory changes affecting early stage R&D in China?
BIO-Europe® 2016: How are regulatory changes affecting early stage R&D in China?

Darren Ji, former VP and global head of Asia and emerging markets at Roche, chats with Mike Ward, global di...

Next Video
BIO-Europe® 2016: Peter Fong on Genentech's science shopping list, recent BioNtech deal
BIO-Europe® 2016: Peter Fong on Genentech's science shopping list, recent BioNtech deal

"Peter Fong, associate director of oncology business development at Genentech Inc. (a division of Roche), s...